NLR as a Prognostic Biomarker in Patients With Advanced RCC Treated With Avelumab Plus Axitinib or Sunitinib
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Association of Neutrophil-to-Lymphocyte Ratio With Efficacy of First-Line Avelumab Plus Axitinib vs Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial
Clin. Cancer Res 2021 Nov 17;[EPub Ahead of Print], MA Bilen, BI Rini, MH Voss, J Larkin, JBAG Haanen, L Albiges, LC Pagliaro, EG Voog, ET Lam, N Kislov, BA McGregor, AA Lalani, B Huang, A di Pietro, S Krulewicz, PB Robbins, TK ChoueiriFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.